razaxaban has been researched along with bms 740808 in 5 studies
| Studies (razaxaban) | Trials (razaxaban) | Recent Studies (post-2010) (razaxaban) | Studies (bms 740808) | Trials (bms 740808) | Recent Studies (post-2010) (bms 740808) |
|---|---|---|---|---|---|
| 20 | 0 | 2 | 5 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, RS; Amparo, E; Bai, S; Ellis, C; Galemmo, RA; Han, Q; He, K; He, MY; Kettner, C; Knabb, RM; Lam, PY; Luettgen, JM; Mersinger, L; Orwat, MJ; Pinto, DJ; Quan, ML; Rendina, AR; Rossi, KA; Smallwood, A; Wells, B; Wexler, RR; Wong, PC | 1 |
| Alexander, RS; Clark, C; Galemmo, RA; He, K; Knabb, RM; Lam, PY; Li, R; Luettgen, JM; Orwat, MJ; Pinto, DJ; Quan, ML; Rendina, AR; Rossi, KA; Smallwood, A; Wells, B; Wexler, RR; Woerner, F; Wong, PC | 1 |
| Alexander, RS; He, K; Knabb, RM; Koch, S; Lam, PY; Luettgen, JM; Orwat, MJ; Pinto, DJ; Rendina, AR; Rossi, KA; Smallwood, A; Wexler, RR; Wong, PC; Xin, B | 1 |
| Bai, S; Galemo, RA; He, K; Knabb, RM; Lam, PY; Luettgen, JM; Orwat, MJ; Pinto, DJ; Theroff, JP; Varnes, JG; Wacker, DA; Wells, B; Wexler, RR | 1 |
| Cheney, DL; Knabb, RM; Pinto, DJ; Smallheer, JM; Wexler, RR | 1 |
1 review(s) available for razaxaban and bms 740808
| Article | Year |
|---|---|
Factor Xa inhibitors: next-generation antithrombotic agents.
Topics: Administration, Oral; Animals; Anticoagulants; Biological Availability; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Hemostasis; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Thrombosis | 2010 |
4 other study(ies) available for razaxaban and bms 740808
| Article | Year |
|---|---|
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of bloo
Topics: Factor Xa Inhibitors; Models, Molecular; Pyrazoles; Pyridones; Serine Proteinase Inhibitors | 2006 |
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties.
Topics: Administration, Oral; Benzamides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Treatment Outcome | 2006 |
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
Topics: Administration, Oral; Animals; Biological Availability; Blood Coagulation; Crystallography, X-Ray; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; In Vitro Techniques; Models, Molecular; Molecular Structure; Pyrazoles; Pyridones; Rabbits; Structure-Activity Relationship | 2007 |
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
Topics: Animals; Caco-2 Cells; Dogs; Factor Xa Inhibitors; Humans; Pyrazoles; Serine Proteinase Inhibitors; Structure-Activity Relationship | 2008 |